Oversold_Gems Posted - 4 days ago

$ANAB

Doozio Posted - 04/30/24

$ANAB feb started this 🐑 correction bahhht if XBI goes Roger n no faatch 💣 land in chop chop huckleberries 🧠⏰?

Oversold_Gems Posted - 04/30/24

$ANAB

GSP Posted - 04/17/24

$ANAB has more than filled the gap from 5 days ago, and it's back down to support. It may give us a long setup tomorrow, so it makes the chat room watch list.

GSP Posted - 04/17/24

Day Trading Watch List Video for April 18th (con't): $ANAB $CUTR $ZUO $INDO $RENT Watch here: https://greatstockpix.com/april-18th-day-trading-watch-list/

Stocksrunner Posted - 04/17/24

📈 Analyst Upgrades Today: $ANAB Leerink Partners initiates coverage of AnaptysBio with an Outperform recommendation. Potential growth ahead! $GCT GigaCloud Technology earns a Strong Buy rating, indicating promising prospects according to SA Quant. $RCL Mizuho assigns a Buy rating to Royal Caribbean, citing its strong asset mix and appealing destinations. $FCX Freeport-McMoRan highlighted on CNBC's Final Trades. Analysts at Morgan Stanley maintain an Equal-Weight rating with a raised price target, reflecting positive sentiment. $OMC rises as Wells Fargo upgrades, foreseeing trends favoring strong EPS growth. https://stocksrunner.com/upgrades Stay informed with these analyst insights!

Oversold_Gems Posted - 04/17/24

$ANAB

Thestocktraderhubzee Posted - 04/17/24

WATCHLIST APR 17 2024.. $DASH Deutsche Bank Maintains Buy on DoorDash, Raises Price Target to $155 $VUZI Craig-Hallum Maintains Buy on Vuzix, Lowers Price Target to $3 $ANAB Leerink Partners Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $47 $WFRD Raymond James Maintains Strong Buy on Weatherford International, Raises Price Target to $152 $USAC Raymond James Maintains Outperform on USA Compression Partners, Raises Price Target to $30

G101SPM Posted - 04/16/24

$ANAB $21.87 bid. DAC $24.93. EXIT $35.00. NEWS: AnaptysBio (ANAB) initiated with an Outperform at Leerink Partners; tgt $47.

G101SPM Posted - 04/11/24

$ANAB $25.16 bid. DAC (dollar average cost) $24.93 (2.22.24). EXIT $35.00. UPDATE: AnaptysBio (ANAB) initiated with an Overweight at Wells Fargo; tgt $56.

SmartestMoney Posted - 04/11/24

$ANAB 😴 ⏰

StockBraker Posted - 04/11/24

$ANAB has been initiated by Wells Fargo as a overweight at 56.0.

DonCorleone77 Posted - 03/31/24

$ANAB AnaptysBio price target lowered to $28 from $30 at JPMorgan JPMorgan lowered the firm's price target on AnaptysBio to $28 from $30 and keeps a Neutral rating on the shares. The analyst updated the company's model to include expenses and share count.

insiderbuyingselling Posted - 03/26/24

$ANAB new insider selling: 148940 shares. http://insiderbuyingselling.com/?t=ANAB

StockBraker Posted - 03/14/24

$ANAB Price is incorrect - There have been no trades PM thus far.

_StockTrader Posted - 03/12/24

Real-Time Stock Data $ANAB Price: 25.98 Volume: 259805 Market Cap: 687266496 PE Ratio: -9.5 Powered by: SHOT

SmartestMoney Posted - 03/12/24

$ANAB Tick tock

G101SPM Posted - 03/12/24

$ANAB $23.35 last. DAC $24.93 (2.22.24). EXIT $35.00. NEWS: Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20

epsguid Posted - 03/11/24

$ANAB reported a loss of $1.59, consensus was ($1.74) via @eWhispers #epsbeat http://eps.sh/d/anab

DonCorleone77 Posted - 03/11/24

$ANAB AnaptysBio reports Q4 EPS ($1.59), consensus ($1.60) Reports Q4 revenue $9.01M, consensus $2.23M. Collaboration revenue was $9M compared to $6.8M last year. The change is due primarily to increased royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022. "2023 was a remarkable year for Anaptys as we implemented a multi-year development plan investing across our best-in-class immune cell modulators (ICMs) to bring transformational medicines to patients living with heterogeneous, systemic autoimmune and inflammatory diseases, with the goal of restoring immune balance," said Daniel Faga, president and chief executive officer of Anaptys. "Enrollment is ongoing in three global Phase 2 trials for ANB032, our BTLA agonist, in atopic dermatitis and rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ulcerative colitis. Additionally, we expanded our portfolio by acquiring the rights to ANB101, a BDCA2 modulator...."

Stock_Titan Posted - 03/11/24

$ANAB Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/ANAB/anaptys-announces-fourth-quarter-and-full-year-2023-financial-k6lla7fyagx7.html

G101SPM Posted - 02/29/24

$ANAB $26.08 bid. DAC $24.93 (2.28.24). EXIT $35.00. UPDATE: Today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference. ^Additionally, the company announced an upcoming presentation at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA, March 8-12, 2024. The oral presentation will focus on preclinical ANB032 (BTLA agonist) data supporting the modulation of dendritic cell (DC) maturation and function as a novel mechanism to address atopic dermatitis pathophysiology. ^Investor Conference Details Event – TD Cowen’s 44th Annual Health Care Conference Format – Corporate panel discussion and one-on-one investor meetings Panel Title – Inflammation & Immunology Corporate Panel Discussion Date and Time – Tuesday, March 5, 2024 at 2:10pm ET / 11:10am PT

Stock_Titan Posted - 02/29/24

$ANAB Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting https://www.stocktitan.net/news/ANAB/anaptys-to-present-at-td-cowen-s-44th-annual-health-care-conference-6orbnjdqbuu0.html

StockBraker Posted - 02/28/24

@Arlington28 I also own $BLUE, $EDIT, $ANAB, $MRNA, $BIIB, etc - Feel free to share your wisdom on those boards too.

SmartestMoney Posted - 02/26/24

$ANAB Yes

Quantumup Posted - 02/26/24

BTIG initiated $ANAB Buy/$55 BTIG believes $ANAB's PD-1/BTLA agonists are well-positioned to emerge as BiC. $LLY's peresolimab has meaningfully de-risked PD-1 class /sees >75% upside vs 20-40% downside if $LLY's P2B data confirms earlier P2A data and/or their Tx progresses. $jnj $sny $gsk

StockBraker Posted - 02/26/24

$ANAB has been initiated by BTIG Research as a buy at 55.0.

G101SPM Posted - 02/26/24

$ANAB $26.14. DAC $24.923 (2.22.24). EXIT $35.00. UPDATE: BTIG Research initiates ANAB with a Buy and price target of $55. Analyst Julian Harrison added, "Checkpoint agonism in autoimmune disease remains underexplored and ANAB is pursuing this broad opportunity with PD-1 and BTLA agonists that are well-positioned to emerge as best-in-class. We expect Phase 2b peresolimab data that confirms the efficacy seen in Phase 2a (reviewed below) and/or a clear indication of LLY progressing peresolimab into pivotal development to unlock significant upside for ANAB shares (likely >75%); the exact timing is unclear, but directional clarity is expected in 2024. Phase 2b data of ANB023 in AD are expected YE24, and we expect strength in ANAB shares through the catalyst."

Stocksrunner Posted - 02/25/24

📈 Sunday Buzz in the Headlines $CROX: Crocs defies skeptics, emerges as a top-performing shoe stock. Price target sees a 9.54% boost to $139.66. $OXY: Warren Buffett's annual letter clarifies: Berkshire won't buy Occidental. Insights from the Oracle of Omaha guide market sentiment. $TEVA: Alvotech and Teva celebrate FDA approval for SIMLANDI®. The first interchangeable high-concentration biosimilar to Humira® gains traction. $ANAB: AnaptysBio receives a significant price target boost of 40.21% to $38.61. Positive outlook reinforces investor confidence. 📊 Stay informed, trade wisely! https://stocksrunner.com/home

NorthWestHawk Posted - 02/22/24

$ANAB is also getting closer to its 52-week high. Ecor1 Capital (Oleg Nodelman) is the largest stockholder (at 28%) among all hedge funds.